Serotonin 3 receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Serotonin 3 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Serotonin 3 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Serotonin 3 Receptor Antagonists: Overview
Serotonin receptor (5-HT3AR) is the most common therapeutic target to manage the nausea and vomiting during cancer therapies and in the treatment of irritable bowel syndrome. Setrons, a class of competitive antagonists, cause functional inhibition of 5-HT3AR in the gastrointestinal tract and brainstem, acting as effective anti-emetic agents.
Function – The 5-HT3 receptors, like nicotinic acetylcholine (nACh), GABAA/C, and glycine receptors, are members of the Cys-loop family of pentameric ligand-gated ion channels. They play important roles in fast neurotransmission in the central and peripheral nervous systems. 5-HT3 receptors are located primarily in the chemoreceptor trigger zone in the area postrema and in the gastrointestinal (GI) tract, where they have roles in regulating gut motility and the emesis reflex.
Serotonin 3 Receptor Antagonists- Serotonin (5-HT3) receptor antagonists are commonly used to decrease nausea and vomiting for surgery patients. Selective serotonin receptor (5-HT3) antagonists block serotonin both peripherally, on gastrointestinal (GI) vagal nerve terminals, and centrally in the chemoreceptor trigger zone. This blockade results in powerful antiemetic effects.
Serotonin 3 Receptor Antagonists Emerging Drugs Chapters
This segment of the Serotonin 3 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Serotonin 3 Receptor Antagonists Emerging Drugs
Further product details are provided in the report……..
Serotonin 3 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Serotonin 3 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Serotonin 3 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Serotonin 3 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Serotonin 3 Receptor Antagonists drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Serotonin 3 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Serotonin 3 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Serotonin 3 Receptor Antagonists: Overview
Serotonin receptor (5-HT3AR) is the most common therapeutic target to manage the nausea and vomiting during cancer therapies and in the treatment of irritable bowel syndrome. Setrons, a class of competitive antagonists, cause functional inhibition of 5-HT3AR in the gastrointestinal tract and brainstem, acting as effective anti-emetic agents.
Function – The 5-HT3 receptors, like nicotinic acetylcholine (nACh), GABAA/C, and glycine receptors, are members of the Cys-loop family of pentameric ligand-gated ion channels. They play important roles in fast neurotransmission in the central and peripheral nervous systems. 5-HT3 receptors are located primarily in the chemoreceptor trigger zone in the area postrema and in the gastrointestinal (GI) tract, where they have roles in regulating gut motility and the emesis reflex.
Serotonin 3 Receptor Antagonists- Serotonin (5-HT3) receptor antagonists are commonly used to decrease nausea and vomiting for surgery patients. Selective serotonin receptor (5-HT3) antagonists block serotonin both peripherally, on gastrointestinal (GI) vagal nerve terminals, and centrally in the chemoreceptor trigger zone. This blockade results in powerful antiemetic effects.
Serotonin 3 Receptor Antagonists Emerging Drugs Chapters
This segment of the Serotonin 3 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Serotonin 3 Receptor Antagonists Emerging Drugs
- AD04 (ondansetron): Adial Pharmaceuticals
- DS-001: DAS Therapeutics
Further product details are provided in the report……..
Serotonin 3 Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Serotonin 3 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Serotonin 3 Receptor Antagonists
- Phases
- Late-stage products (Phase III )
- Mid-stage products (Phase II )
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intravenous
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Serotonin 3 Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Serotonin 3 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Serotonin 3 Receptor Antagonists drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Serotonin 3 Receptor Antagonists R&D.
- The therapies under development are focused on novel approaches for Serotonin 3 Receptor Antagonists.
- Serotonin 3 Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Serotonin 3 Receptor Antagonists drugs?
- How many Serotonin 3 Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Serotonin 3 Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Serotonin 3 Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Serotonin 3 Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Serotonin 3 Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Serotonin 3 Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Serotonin 3 Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Serotonin 3 Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AD04 (ondansetron): Adial Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DS-001: DAS Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CAM2047: Camurus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Serotonin 3 Receptor Antagonists Key Companies
Serotonin 3 Receptor Antagonists Key Products
Serotonin 3 Receptor Antagonists- Unmet Needs
Serotonin 3 Receptor Antagonists- Market Drivers and Barriers
Serotonin 3 Receptor Antagonists- Future Perspectives and Conclusion
Serotonin 3 Receptor Antagonists Analyst Views
Serotonin 3 Receptor Antagonists Key Companies
Appendix
Executive Summary
Serotonin 3 Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Serotonin 3 Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Serotonin 3 Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Serotonin 3 Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AD04 (ondansetron): Adial Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DS-001: DAS Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CAM2047: Camurus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Serotonin 3 Receptor Antagonists Key Companies
Serotonin 3 Receptor Antagonists Key Products
Serotonin 3 Receptor Antagonists- Unmet Needs
Serotonin 3 Receptor Antagonists- Market Drivers and Barriers
Serotonin 3 Receptor Antagonists- Future Perspectives and Conclusion
Serotonin 3 Receptor Antagonists Analyst Views
Serotonin 3 Receptor Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Serotonin 3 Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Serotonin 3 Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Serotonin 3 Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Serotonin 3 Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
